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Abstract
Background: Previous reports indicate an association between autism spectrum disorders (ASD) and disorders of
mitochondrial oxidative phosphorylation. One study suggested that children with both diagnoses are clinically
indistinguishable from children with idiopathic autism. There are, however, no detailed analyses of the clinical and
laboratory findings in a large cohort of these children. Therefore, we undertook a comprehensive review of patients with
ASD and a mitochondrial disorder.
Methodology/Principal Findings: We reviewed medical records of 25 patients with a primary diagnosis of ASD by DSM-IV-
TR criteria, later determined to have enzyme- or mutation-defined mitochondrial electron transport chain (ETC) dysfunction.
Twenty-four of 25 patients had one or more major clinical abnormalities uncommon in idiopathic autism. Twenty-one
patients had histories of significant non-neurological medical problems. Nineteen patients exhibited constitutional
symptoms, especially excessive fatigability. Fifteen patients had abnormal neurological findings. Unusual developmental
phenotypes included marked delay in early gross motor milestones (32%) and unusual patterns of regression (40%). Levels
of blood lactate, plasma alanine, and serum ALT and/or AST were increased at least once in 76%, 36%, and 52% of patients,
respectively. The most common ETC disorders were deficiencies of complex I (64%) and complex III (20%). Two patients had
rare mtDNA mutations of likely pathogenicity.
Conclusions/Significance: Although all patients’ initial diagnosis was idiopathic autism, careful clinical and biochemical
assessment identified clinical findings that differentiated them from children with idiopathic autism. These and prior data
suggest a disturbance of mitochondrial energy production as an underlying pathophysiological mechanism in a subset of
individuals with autism.
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Autism spectrum disorders (ASD) are neurodevelopmental
disorders characterized by impaired social interaction and
communication, as well as isolated interests and repetitive or
stereotyped behaviors [1]. ASDs pose a significant burden to
affected individuals, their families and society. This burden comes
both from the debilitating and lifelong nature of ASDs and from
their prevalence. It is now estimated that about one out of every
166 children is affected with ASD [2]. Most cases are idiopathic,
although there are many uncommon or rare genetic and metabolic
causes of autism that are increasingly recognized [3–5].
In 1998, Lombard postulated mitochondrial dysfunction as a
cause of autism [6]. Prior and subsequent case reports provided
biochemical data indicating perturbation of mitochondrial energy
metabolism in some individuals with ASD [7–12], including
mtDNA mutations in several [10,13,14]. Recently, Oliveira and
colleagues published a population-based survey of school-age
children with ASD. They found that 7% of those who were fully
tested met criteria for definite mitochondrial respiratory chain
disorders and were also clinically indistinguishable from other
children with ASD [15]. This work is notable because it suggests
that mitochondrial disorders of energy production may be present
in a substantial percentage of children with ASD. To better
describe the clinical spectrum of children with ‘mitochondrial
autism’, we undertook a chart review of the biochemical, genetic,
and histopathological findings in 25 patients with ASD who had
unequivocal evidence of a disorder of oxidative phosphorylation.
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Subject Determination
We reviewed medical records of 25 children with a diagnosis of
ASD according to DSM-IV-TR criteria [16] and evidence of a
disorder of mitochondrial energy metabolism evaluated by one of
our investigators at Cleveland Clinic, Massachusetts General
Hospital/LADDERS Program, or Kennedy Krieger Institute.
The study was approved by the Institutional Review Boards (IRBs)
of these institutions and is in accord with the principles of the
Declaration of Helsinki. The IRBs determined that this chart
review study met criteria for waiver of consent.
Children were referred for genetic and/or metabolic evaluation of
autism but not specifically for evaluation for mitochondrial disease.
Children with known chromosomal or monogenic disorders were
excluded. All patients met criteria for probable or definite
mitochondrial disease by both the Modified Walker Criteria and
the Mitochondrial Disease Criteria (MDC) [17,18]. All patients also
had either: (1) ,20% activity of one or more muscle or fibroblast
electron transport chain (ETC) activities; (2) ,2 standard deviations
below the control mean of one or more ETC complexes by
polarographicanalysis; (3) a mitochondrial DNA sequence variant of
probable pathogenicity plus biochemical evidence of mitochondrial
dysfunction; or (4) clinical and biochemical data consistent with a
mitochondrial disorder and a sib with enzyme-defined ETC
dysfunction. One patient was reported earlier [12].
Clinical and Biochemical Data
Medical records of each patient were independently reviewed
by at least two members of the study team. Growth parameters
were evaluated using the ABase software and North American
pediatric reference values [19]. Institution specific reference
intervals were used for assessments of blood lactate and pyruvate,
plasma alanine, urinary organic acids, CK, AST, and ALT.
Biochemical evidence of mitochondrial ETC dysfunction included
increased blood lactate and pyruvate levels, elevated plasma
alanine level, and increased urinary levels of Krebs cycle
intermediates or 3-methylglutaconate.
Pathology and Enzyme Data
Twenty-three of the 25 children underwent quadriceps muscle
biopsies, 11 had skin biopsies, and one had a liver biopsy. Three
patients had sibs with muscle biopsies. Muscle ETC determina-
tions were performed at either Horizon Molecular Medicine,
LLC, Atlanta [20,21] or the Center for Inherited Disorders of
Energy Metabolism (CIDEM) Lab, Cleveland [22]. Muscle biopsy
specimens were either snap frozen then shipped for ETC
determination in homogenates or muscle mitochondria were
isolated from fresh muscle biopsy specimens with aliquots frozen
for subsequent determination of ETC activities. Functional
(polarographic) analyses of oxidative phosphorylation using freshly
isolated muscle mitochondria were performed at CIDEM [22].
ETC determinations of skin fibroblasts were done at CIDEM [23]
or Mayo Laboratories. Fibroblast lactate and pyruvate measure-
ments were performed at The Hospital for Sick Children, Toronto
[24]. ETC activities were normalized to the mitochondrial marker
enzyme citrate synthase, or if citrate synthase activity was not
assayed, the percent of the mean of controls was used.
Mitochondrial DNA (mtDNA) Mutation Data
Sixteen of 25 children underwent analyses for selected
mitochondrial mutations and 11 of 25 patients had mtDNA
mutation analysis by dHPLC of the entire mitochondrial genome
at Transgenomic, Inc, Omaha [25]. Each DNA sequence variant
was evaluated for pathogenicity by a search of the MITOMAP
and mtDB–Human Mitochondrial Genome databases [26,27],
PubMed, and compendia of mtDNA mutations including
guidelines for determination of pathogenicity [28,29].
Results
Clinical Characteristics of Subjects (Table 1; Tables S1, S2,
S3)
Twenty-five patients–13 males and 12 females ages 2–20 years–
were included in this analysis; 11 patients met DSM-IV-TR criteria
for autistic disorder and 14 met DSM-IV-TR criteria for PDD-
NOS. Twenty-one patients had definite mitochondrial disease and
four had probable mitochondrial disease by the Modified Walker
Criteria. Eleven patients met criteria for definite mitochondrial
disease and 14 met criteria for probable disease using the MDC.





Multiple gestation birth 83 2
Prenatal or perinatal complications 13 52
Cardiovascular abnormality 72 8
GI dysfunction 16 64






Growth retardation (,2 SD for weight
and/or height)
52 0
Microcephaly (,2 SD) 41 6
Macrocephaly (.3 SD) 41 6
Fatigability/exercise intolerance 17 68





Oculomotor abnormality 41 6
Ptosis 28
Sensorineural hearing deficit 31 2
Dysarthria 31 2
Multiple regressions 93 6
Regression(s) after three years of age 62 4
At least 1 major clinical finding
uncommon in ASD**
24 96
At least 1 non-CNS organ system
involved
21 84
At least 2 non-CNS organ systems
involved
83 2
At least 1 neurologic finding uncommon
in ASD{
15 60
*Defined as $5 SD from mean age at walking [33].
**Does not include multiple gestation birth, prenatal/perinatal complications,
GERD, constipation or macrocephaly.
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medical problems, most commonly of the gastrointestinal system,
with gastroesophageal reflux affecting nine and constipation
affecting eight subjects. Seven patients had structural or functional
cardiovascular abnormalities. In addition, 17 patients had
excessive fatigability or exercise intolerance and several children
had abnormal physical exam findings including six with facial
dysmorphism, four with microcephaly, four with macrocephaly,
and five with growth retardation.
Twelve patients had neurological findings uncommon in ASD
apart from microcephaly, including: oculomotor abnormalities
(n=4), sensorineural hearing deficit (n=3), dysarthria (n=3), ptosis
(n=2), movement disorders (n=2), and hypertonia (n=1). Five
patients had seizures with one having medically refractory epilepsy.
Eight patients had markedly delayed early motor milestones. Of
14 patients with regression of previously acquired skills, nine had
multiple regressions, six regressed at ages older than three years,
and seven had regressions occurring with infections or other
metabolic stresses. In six, gross motor skills were lost in addition to
language skills. In one case, the timing of regression coincided with
a recent vaccination.
Family history data were notable for likely autosomal recessive
inheritance in one patient whose parents were first cousins. The
family history suggested mitochondrial inheritance in three
patients. Three other patients had mothers with features
suggesting mitochondrial disease and four patients had sibs with
either enzyme-defined mitochondrial disease and/or a clinical
history consistent with mitochondrial disease.
Biochemical and Neuroimaging Data (Table 2; Tables S4
and S5)
Blood lactate was measured in all patients; 19 had at least one
increased lactate level, 13 had multiple high levels and 14 had at
least one lactate level greater than 3 mmol/L. Of 17 patients who
had at least one blood pyruvate determination, nine (53% of those
tested) had at least one increased pyruvate level. Plasma amino
acids were analyzed for all patients; nine had at least one increased
plasma alanine level and four had multiple high alanine levels.
The level of AST and/or ALT was increased in 13. One patient
had an increased ALT with a normal AST and seven had elevated
AST with normal ALT. Eight patients (28%) had increased serum
CK levels. Ten patients (42% of those tested) had urinary organic
acid abnormalities indicative of mitochondrial dysfunction. The
fibroblast lactate/pyruvate ratio was increased for three patients.
Twenty-one patients underwent cranial MRI studies; five also
had cranial MRS. Ten children had abnormalities on MRI (48%
of those imaged), without a single finding predominating, while
two patients had increased lactate on MRS (40% of those imaged).
Histological and Ultrastructural Findings (Table 3)
The most common histological abnormalities in muscle were
atrophic or regenerating fibers (n=8), reduced cytochrome
oxidase (COX) staining (n=6), variation in fiber size (n=5), and
increased myofiber lipid (n=5). The most common ultrastructural
abnormalities were abnormal mitochondrial morphology (n=4)
and increased number of mitochondria (n=4).
Enzyme and Mitochondrial Mutation Data (Table 4; Table
S6)
Twenty patients had deficient activity of a respiratory chain
complex on tissue ETC or polarographic analysis; three others had
phenotypes and biochemical profiles consistent with mitochondrial









Increased blood lactate level 19 25 76
Increased blood pyruvate level 91 7 5 3
Increased plasma alanine level 92 5 3 6
Increased serum AST and/or ALT
level
13 25 52
Increased serum CK level 82 5 3 2





31 5 2 0
Biochemical evidence of
mitochondrial disease with any
of the above tests
24 25 96
Abnormal cranial MRI 10 21 48
Increased lactate on cranial MRS 25 4 0
doi:10.1371/journal.pone.0003815.t002
Table 3. Muscle Histology and Ultrastructure.
Number of patients
Moderate to large variation in fiber size 5
Atrophic or regenerating fibers 8
Focal inflammation 4
Increased myofiber lipid content 5
Type I fiber predominance 1
COX-negative fibers or reduced COX staining 6
Ragged red fibers 2
Increased number or subsarcolemmal
aggregates of mitochondria
4
Mitochondria with abnormal morphology 4
doi:10.1371/journal.pone.0003815.t003





Complex I defect 16 64
Complex II defect 28
Complex III defect 52 0
Complex IV defect 14
mtDNA tRNA mutation 14
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determination. Specific abnormalities included complex I defect in
16, complex III defect in five, complex II defect in two, and
complex IV defect in one. Two patients had mtDNA mutations of
likely pathogenicity and four had mtDNA sequence variants of
unclear pathogenicity.
Discussion
The cohort of 25 patients reported here comprises the largest
group of individuals with co-occurrence of ASD and defective
oxidative phosphorylation reported to date. While previous case
reports implicated an association of ASD and mitochondrial
dysfunction, it could be argued that this was a chance occurrence
in those individuals. Recent epidemiological studies indicate a
population prevalence of ASD in about one in 166 children [2] and
of mitochondrial disease in about one in 5–10,000 children [30,31].
Thesedata,and theoccurrenceofdefiniteoxidative phosphorylation
dysfunction in approximately 7% of children with ASD in a
population-based cohort [15], provide an epidemiological argument
for a non-chance occurrence of ASD and mitochondrial disorders.
Our results indicate diverse and complex developmental,
neurological, and medical phenotypes of persons with mitochon-
drial autism, nearly all of which differ from those of patients with
idiopathic ASD. Although many children with ASD exhibit some
degree of hypotonia, most attain their early gross motor milestones
on time [32]. In contrast, 64% of our patients were delayed in
attaining early developmental milestones and 32% were five or
more standard deviations later than the mean in walking
independently [33]. In addition, although regression has been
reported to occur in approximately one third of autistic children,
typically before age three years [34], 40% of our patients
demonstrated unusual patterns of regression–either repeated
regressions, regressions involving losses of gross motor function,
and/or regressions after age three years.
Recently, there has been increased concern regarding a possible
causative role of vaccinations in autistic children with an
underlying mitochondrial cytopathy [35,36]. For one of our 25
patients, the child’s autism/neurodevelopmental deterioration
appeared to follow vaccination [12,36]. Although there may have
been a temporal relationship of the events in this case, such timing
does not prove causation. That said, there might be no difference
between the inflammatory or catabolic stress of vaccinations and
that of common childhood diseases, which are known precipitants
of mitochondrial regression [37]. Large, population-based studies
will be needed to identify a possible relationship of vaccination
with autistic regression in persons with mitochondrial cytopathies.
In addition to atypical developmental patterns, non-neurological
disorderswerenearly universalinour patients. Although medicalco-
morbiditiesarenotuncommoninindividualswith ASD,theyarenot
reported tobe present with thehigh frequencynoted here [38].Asin
persons with idiopathic ASD, gastrointestinal dysfunction represent-
ed the most common non-neurological abnormality in our cohort.
However, several of our patients had pancreatic dysfunction or liver
disease–gastrointestinal disorders that are rare in persons with ASD
[39,40]. The other organ system dysfunctions in our patients
(cardiac, hematological, growth retardation, fatigability) are known
manifestations of mitochondrial disease [41–43] but are not typical
co-morbidities of primary autism [38].
Along with medical co-morbidities, an increased frequency of
prenatal and perinatal complications has been reported in children
with ASD [44]. However, whether these complications themselves
increase the risk for autism or are consequences of an underlying
disorder that predisposes to autism is unknown. Our study also
shows a high frequency of prenatal/perinatal complications whose
relationship to the children’s autism is similarly unclear. Of note,
an increased incidence of prenatal/perinatal complications has
been reported for children with mitochondrial disease [45].
Besides prenatal complications, our data indicate a high
frequency of multiple gestation births. The relevance of this
finding is unclear but interesting in view of previous controversy
about twinning as a risk factor for autism [46].
Also dramatically different from the general ASD population,
the sex distribution of the subjects in our cohort is approximately
1:1. Primary ASD is 3–6 times more common in males than
females and this ratio is even higher in PDD-NOS [1,2]. Since
56% of our patients have PDD-NOS, our finding of a nearly even
distribution of males and females is especially notable.
From a biochemical perspective, patients’ blood and urine
laboratory data revealed marked interindividual variation that did
not appear to correspond with specific ETC defects or clinical
phenotypes. Significant intraindividual variation was also noted for
determinations of blood lactate and pyruvate levels, plasma
alanine levels, serum transaminases and CPK, and urinary organic
acids, with intermittent normal levels in most cases. The
histological and ultrastructural abnormalities noted on muscle
biopsies were also varied amongst the subjects of this cohort and
similar to results noted in other cohorts of children with
mitochondrial electron transport chain disorders [47].
For most individuals with defects of oxidative phosphorylation,
the diagnosis is made through ETC determination but an
underlying nuclear or mitochondrial mutation usually cannot be
identified [43,48,49]. The biochemical assessment of mitochon-
drial disorders, especially ETC enzyme assay, is complex and
subject to limitations [49,50]. Even a clear-cut deficiency of one or
more ETC activities in vitro does not prove a genetic defect of
oxidative phosphorylation because ETC deficiencies can be
secondary to other conditions [41,49–51]. The biochemical cut-
off to diagnose a deficiency of an ETC varies by laboratory and
multiple sets of diagnostic criteria are in use [49]. The criteria used
in this study reflect an attempt to be diagnostically conservative.
We excluded patients with clearly reduced but .20% ETC
activity who lacked a pathogenic mutation even though less
restrictive criteria are commonly used.
ETC complex I deficiency was the most prevalent enzyme
defect, affecting 64% of our patients, followed by complex III
deficiency, affecting 20%. It should be noted, however, that we
cannot exclude the possibility that some patients might have
biochemically mild forms of multiple ETC deficiencies. The
predominance of ETC complex I deficiency is not unexpected and
has been noted in cohorts of non-autistic patients with mitochon-
drial cytopathies [52]. This presumably reflects the large number
of genes encoding complex I structure, assembly, and regulation.
Of patients who underwent mitochondrial genomic analysis,
two had rare homoplasmic DNA sequence variants of likely
pathogenicity: mtDNA 3397A.G and 4295A.G. mtDNA
3397A.G, which replaces methionine with valine in a highly
conserved region of the ND1 subunit of complex I, has been
implicated in various neurological phenotypes and other condi-
tions [53–56]. Our interpretation of its likely pathogenicity is also
based on the patient’s reduced muscle ETC complex I activity and
increased fibroblast lactate:pyruvate ratio. mtDNA 4295A.G
occurs in an absolutely evolutionarily conserved sequence of mt
tRNA
Ileu, reduces 39 tRNAse processing efficiency [57], segregates
with multiple disease states [58–60], and has been categorized as
probably pathogenic [29]. A third patient had a rare sequence
variant, 11984T.C. This mutation, reported previously in a child
with Leigh syndrome, is likely pathogenic as it is a missense
Mitochondrial Autism
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conserved tyrosine with histidine that, in turn, is predicted to
markedly alter protein structure [61]. Its rarity and the absence of
in vitro functional studies preclude assignment of probable
pathogenicity at this time. For all three patients with these
mutations there was intrafamilial phenotypic heterogeneity, as well
as differences from phenotypes reported in the literature.
Undetected heteroplasmy could explain these differences, but
intrafamilial phenotypic variation with homoplasmic mitochon-
drial mutations has been reported and reasonable explanations
proposed [42,62,63]. Because of the variability of phenotypes
associated with these putative mutations, it is possible that there
are important environmental or genetic factors in addition to the
mtDNA mutation that contribute to the development of autism in
a child with one of these mtDNA mutations. The mutations noted
here are different from those described in prior case reports of
children with autism and mitochondrial disease [10,13,14].
Overall, our results demonstrate substantial clinical heteroge-
neity of individuals with co-occurring autism and defects of
mitochondrial oxidative phosphorylation, nearly all of whom we
found to be clinically distinct from children with idiopathic autism.
The data do not exclude the possibility of persons with isolated
autism having a disorder of oxidative phosphorylation–in fact, one
of our patients did not have any major clinical features that
distinguished her from typical autism. In addition, it is possible, if
not likely, that a still broader clinical, biochemical and genetic
spectrum of mitochondrial autism exists.
Finally, data from multiple disciplines, especially research in
developmental neurobiology and genetics, point to several underly-
ing pathophysiological mechanisms in autism, including altered
neurite morphology, synaptogenesis and cell migration due to
abnormalities in distinct ensembles of proteins and pathways [64].
The data reported here, and other cases of mitochondrial autism,
argue that defective mitochondrial oxidative phosphorylation is an
additional pathogenetic basis for a subset of individuals with autism.
Supporting Information
Table S1 ASD Diagnosis and Mitochondrial Disease Criteria.
PDD-NOS=Pervasive developmental disorder–not otherwise
specified, MDC=mitochondrial disease criteria
Found at: doi:10.1371/journal.pone.0003815.s001 (0.07 MB
DOC)
Table S2 Pertinent Medical History. GERD=gastroesophageal
reflux disease, POTS=postural orthostatic tachycardia syndrome,
RBBB=right bundle branch block, EF=ejection fraction,
LVH=left ventricular hypertrophy
Found at: doi:10.1371/journal.pone.0003815.s002 (0.05 MB
DOC)
Table S3 Regression History. Blank cells indicate an absence of
regression of the type listed in the column
Found at: doi:10.1371/journal.pone.0003815.s003 (0.05 MB
DOC)
Table S4 Biochemical Data. L:P=lactate to pyruvate ratio,
DCA=dicarboxylic acids, EMA=ethylmalonate, 3-MG=3-
methylglutaconate * Value is listed only if level was higher than
the upper limit of the reference interval { Patient had one high
level but exact value is unknown
Found at: doi:10.1371/journal.pone.0003815.s004 (0.06 MB
DOC)
Table S5 Neuroimaging. Blank cells indicate that patient did not
undergo cranial MRI
Found at: doi:10.1371/journal.pone.0003815.s005 (0.04 MB
DOC)
Table S6 Enzymology and mtDNA Testing 1 Testing per-
formed at CIDEM Lab, Cleveland 2 Testing performed at
Horizon Molecular Medicine LLC, Atlanta A: selected point
mutations screened B: mtDNA sequencing C: whole mitochon-
drial genome scan by dHPLC P: mutation of probable
pathogenicity U: mutation of unclear pathogenicity OXPHOS:
polarographic determination of mitochondrial oxidative phos-
phorylation reactions * This patient does not have mitochondrial
sequence changes indicative of haplogroup K {ETC complex III,
when measured separately, was normal in these patients
Found at: doi:10.1371/journal.pone.0003815.s006 (0.06 MB
DOC)
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